• May 18, 2024

GEMAC – Business strategy

GEMAC aims to be a leading drug discovery company focusing on unmet needs in neurosciences and autoimmune diseases.

GEMAC is successfully engaged in the following fields:

Pharmaceuticals: GEMAC is using non-immunogenic molecules in the preparation of therapeutic compounds for the treatment of autoimmune and neurodegenerative diseases (Multiple Sclerosis, Amyotrophic Lateral Sclerosis …).

Drug delivery: GEMAC is working on the use of non-allergenic carrier molecules to transfer small biologically active molecules to their target for a therapeutic purpose (bacteriostatic, anti-allergenic, anti-fungal, anti-inflammatory, immunomodulating activities).

Biological tools: GEMAC is developing biological tools for the monitoring of neurodegenerative diseases. These tools are detecting the antibodies (A and/or M isotype) directed against modified endogenous molecules and bacterial components.

GEMAC’s business model is to rapidly advance its drug candidates into phase II or phase III.